Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.55 USD | -0.95% | +1.61% | +35.42% |
02:00pm | Immunome, Inc. Appoints Kinney Horn as Chief Business Officer | CI |
30/04 | JPMorgan Starts Immunome With Overweight Rating, $24 Price Target | MT |
Business Summary
Number of employees: 55
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biotechnology
100.0
%
| 0 | nan % | 14 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 14 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Clay Siegall
CEO | Chief Executive Officer | 63 | 02/23/02 |
Max Rosett
DFI | Director of Finance/CFO | 34 | 02/23/02 |
Bob Lechleider
CTO | Chief Tech/Sci/R&D Officer | 63 | 19/23/19 |
Matthew Robinson
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/16/01 |
Jack Higgins
CTO | Chief Tech/Sci/R&D Officer | 45 | 02/23/02 |
Philip Wagenheim
BRD | Director/Board Member | 53 | 01/17/01 |
Robert Lapetina
AUD | Comptroller/Controller/Auditor | 49 | 01/21/01 |
Bruce Turner
PRN | Corporate Officer/Principal | 60 | 02/23/02 |
Sandra Stoneman
LAW | General Counsel | 51 | 10/20/10 |
Kinney Horn
PRN | Corporate Officer/Principal | 49 | 01/02 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | 02/01 |
Director/Board Member | 70 | 07/11 | |
Clay Siegall
CEO | Chief Executive Officer | 63 | 02/23/02 |
Philip Wagenheim
BRD | Director/Board Member | 53 | 01/17/01 |
James Boylan
BRD | Director/Board Member | 57 | 02/23/02 |
Isaac Barchas
BRD | Director/Board Member | 56 | 02/23/02 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 59,943,368 | 49,138,414 ( 81.97 %) | 0 | 81.97 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.42% | 881M | |
-1.04% | 104B | |
+6.24% | 97.47B | |
+5.71% | 22.25B | |
-13.32% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.23% | 16.36B | |
+8.58% | 14.39B | |
+39.58% | 12.37B |
- Stock Market
- Equities
- IMNM Stock
- Company Immunome, Inc.